Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Methylphenidate long-acting · 1 trial · 1 indication
The FBB-ADHS is a 20-item rating scale. Each item describes a typical ADHD symptom. The 20 items are divided into 3 subscales: Attention deficits (9 items), hyperactivity (7 items), and impulsiveness (4 items). Each item is rated on a scale of 0 = not at all up to 3 = very much. The FBB-ADHS was completed by teachers on Friday afternoon of each week of the study. A total score (sum of all items divided by 20) was calculated. The total score can range from 0 to 3. A lower score indicates more ADHD.
The FBB-ADHS is a 20-item rating scale. Each item describes a typical ADHD symptom. The 20 items are divided into 3 subscales: Attention deficits (9 items), hyperactivity (7 items), and impulsiveness (4 items). Each item is rated on a scale of 0 = not at all up to 3 = very much. The FBB-ADHS was completed by teachers on Friday afternoon of each week of the study. A total score (sum of all items divided by 20) was calculated. The total score can range from 0 to 3. A lower score indicates more ADHD.
| Arm | Type | Description |
|---|---|---|
| Very light breakfast (VLB) then standard breakfast (SB) | EXPERIMENTAL | Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. |
| Standard breakfast (SB) then very light breakfast (VLB) | EXPERIMENTAL | Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. |
| Name | Type | Description |
|---|---|---|
| Methylphenidate 20 mg long-acting capsules | DRUG | - |
Inclusion Criteria: * Children aged 6-12 * Diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) * Current medication with either 20 mg or 40 mg immediate release methylphenidate Exclusion Criteria: * Concomitant psychiatric disorders requiring pharmacological treatment * Concomitant sever...
Methylphenidate long-acting is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is a small molecule being developed by Novartis AG for this psychiatric condition. The drug is currently in Phase 3 clinical development, meaning it is investigational and has not yet been approved for use.
Methylphenidate long-acting is being developed by Novartis AG, a pharmaceutical company traded on the stock exchange under the ticker symbol NVS. The drug is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and is currently in Phase 3 clinical trials.
Methylphenidate long-acting is in Phase 3 clinical development for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is an investigational drug, meaning it has not yet received regulatory approval. One Phase 3 trial has been completed, involving 150 participants.
Methylphenidate long-acting has one completed Phase 3 clinical trial, identified as NCT00428792. This trial, titled "Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)," enrolled 150 participants in Germany. The study included children aged 6 years and older and was a controlled trial.
Methylphenidate long-acting is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for Attention Deficit Hyperactivity Disorder (ADHD). One Phase 3 trial has been completed, but the drug has not yet received regulatory approval from the FDA or any other health authority.